Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Tabitha E. H. Moses, MS joins Ethics Talk to discuss her article, coauthored with Dr Arash Javanbakht: “How Should Clinicians Determine a Traumatized Patient’s Readiness to Return to Work?”
Aminta Kouyate joins Ethics Talk to discuss her article, coauthored with Drs Nhi Tran and Monica U. Hahn: “Why Professionalism Demands Abolition of Carceral Approaches to Patients’ Nonadherence Behaviors.”